Max Robotics — Global Service Robot Directory + US Certification

About

Masaki Momota is a leading researcher in geriatric oncology, with a focused expertise on frailty assessment and its impact on prostate cancer treatment outcomes. His work centers on integrating the Geriatric 8 (G8) screening tool into urological oncology, demonstrating how frailty—rather than age alone—influences treatment decisions, surgical candidacy, and postoperative recovery. Momota’s major contributions include establishing that frailty is a significant predictor of moderate to severe pain after robot-assisted laparoscopic prostatectomy (RARP) and that it negatively affects quality of life and lower urinary symptoms in the postoperative period. His studies, such as the FRART-PC and FRAP studies, have collectively garnered over 88 citations, underscoring their clinical relevance. Notably, his 2020 paper on G8 screening in 540 prostate cancer patients (40 citations) provides a foundational framework for using this simple tool to guide treatment stratification. Momota’s work is pivotal in shifting prostate cancer care toward a more personalized, patient-centered approach that accounts for physiological resilience.